Nov-11 -
Melanoma Group
EORTC 18952 – Post-operative adjuvant Interferon-alpha 2b (Intron-A) treatment after resection of thick primary melanoma and/or regional lymphnode metastases “intermediate-high dose” vs “intermediate-low dose” Interferon-alpha vs observation.
Randomized phase III trial.
EORTC found that additional interferon treatment improves overall survival, in patients with stage III ulcerated melanoma.
